A peptide corresponding to the neuropilin-1-binding site on VEGF165 induces apoptosis of neuropilin-1-expressing breast tumour cells

被引:109
作者
Barr, MP
Byrne, AM
Duffy, AM
Condron, CM
Devocelle, M
Harriott, P
Bouchier-Hayes, DJ
Harmey, JH [1 ]
机构
[1] Beaumont Hosp, Dept Surg, Royal Coll Surg Ireland, Educ & Res Ctr, Dublin 9, Ireland
[2] Royal Coll Surgeons Ireland, Ctr Synth & Chem Biol, Dept Pharmaceut & Med Chem, Dublin 2, Ireland
[3] Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT7 1NN, Antrim, North Ireland
关键词
VEGF; neuropilin-1; peptide; apoptosis;
D O I
10.1038/sj.bjc.6602308
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is increasing evidence that vascular endothelial growth factor ( VEGF) has autocrine as well as paracrine functions in tumour biology. Vascular endothelial growth factor-mediated cell survival signalling occurs via the classical tyrosine kinase receptors Flt-1, KDR/Flk-1 and the more novel neuropilin (NP) receptors, NP-1 and NP-2. A 24-mer peptide, which binds to neuropilin-1, induced apoptosis of murine and human breast carcinoma cells, whereas a peptide directed against KDR had no effect. Both anti-NP1 and anti-KDR peptides induced endothelial cell apoptosis. Confocal microscopy using 5-(6)-carboxyfluorescein-labelled peptides showed that anti-NP1 bound to both tumour and endothelial cells, whereas anti-KDR bound endothelial cells only. This study demonstrates that NP-1 plays an essential role in autocrine antiapoptotic signalling by VEGF in tumour cells and that NP1-blockade induces tumour cell and endothelial cell apoptosis. Specific peptides can therefore be used to target both autocrine ( tumour cells) and paracrine ( endothelial cells) signalling by VEGF.
引用
收藏
页码:328 / 333
页数:6
相关论文
共 26 条
  • [1] Bachelder RE, 2001, CANCER RES, V61, P5736
  • [2] Bachelder RE, 2003, CANCER RES, V63, P5230
  • [3] Bachelder RE, 2002, CANCER RES, V62, P7203
  • [4] Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis
    Binétruy-Tournaire, R
    Demangel, C
    Malavaud, B
    Vassy, R
    Rouyre, S
    Kraemer, M
    Plouët, J
    Derbin, C
    Perret, G
    Mazie, JC
    [J]. EMBO JOURNAL, 2000, 19 (07) : 1525 - 1533
  • [5] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [6] Receptors for collapsin/semaphorins
    Fujisawa, H
    Kitsukawa, T
    [J]. CURRENT OPINION IN NEUROBIOLOGY, 1998, 8 (05) : 587 - 592
  • [7] Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor:: In vivo expression and antitumor activity
    Gagnon, ML
    Bielenberg, DR
    Gechtman, Z
    Miao, HQ
    Takashima, S
    Soker, S
    Klagsbrun, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) : 2573 - 2578
  • [8] Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
    Gluzman-Poltorak, Z
    Cohen, T
    Herzog, Y
    Neufeld, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (24) : 18040 - 18045
  • [9] Gorski DH, 1999, CANCER RES, V59, P3374
  • [10] Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy
    Harmey, JH
    Bouchier-Hayes, D
    [J]. BIOESSAYS, 2002, 24 (03) : 280 - 283